Genentech Inc.: PharmaVitae Profile

Content

• CHAPTER 1 ABOUT THIS PROFILE
  • Executive summary
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors
  • Data sourcing
  • Sales data
  • Analyst consensus
• CHAPTER 2 EXECUTIVE SUMMARY
  • Key findings
  • Prescription pharmaceutical sales performance, 200113
  • Financial performance, 200113
  • Genentech: PharmaVitae forecasts at a glance
  • Strategic insight
  • Genentech, the leading therapeutic monoclonal antibody player
  • Genentechs relationship with Roche a key factor to success
  • Genentechs Big Three
  • Successful land grab locks out competition
  • Horizontal expansion of key products
  • Genentechs core growth
  • A plethora of future approvals for Avastin the key driver
  • Genentech: Avastin-centered growth strategy
  • SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats
• CHAPTER 3 QUARTERLY NEWS UPDATE
  • Product developments
  • Deals and alliances
  • Product deals
  • Technology deals
  • M&A activity
  • Company announcements
  • Future product milestones
• CHAPTER 4 COMPANY INTRODUCTION
  • Key findings
  • Background
  • Key corporate developments
  • Founding
  • Genentechs first product
  • Genentechs first mAb therapy
  • M&A history
  • Genentechs history with its partner Roche
  • Genentechs agreement with Roche
  • But Roche makes Genentech acquisition bid
  • Genentech makes first acquisition: Tanox
  • Current corporate structure
• CHAPTER 5 COMPANY SALES
  • Key findings
  • Prescription pharmaceutical sales and growth rate analysis, 200113
  • Product analysis
  • Product analysis, 200107
  • Product analysis, 200713
  • Therapy area analysis
  • Therapy area analysis, 200107
  • Therapy area analysis, 200107
  • Therapy area analysis, 200713
  • Therapy area focus, 200113
  • Geographic analysis
  • Geographic analysis, 200107
  • Geographic analysis, 200107
  • Geographic analysis, 200713
  • Geographic focus, 200113
  • Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 200713
  • Core analysis, 200713
  • Expiry analysis, 200713
  • Launch/core/expiry configuration, 200713
  • Molecule type analysis
  • Molecule type analysis, 200107
  • Molecule type analysis, 200713
  • Externalization analysis
  • Externalization analysis, 200107
  • Externalization analysis, 200713
• CHAPTER 6 COMPANY FINANCIALS
  • Key findings
  • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200107
  • Financial statements, 200107
  • Profit and loss account, 200107
  • Balance sheet, 200107
  • Operating costs and profit analysis
  • Operating costs and profit analysis, 200107
  • Operating cost ratio and profit margin analysis, 200107
  • Operating cost ratio and profit margin analysis, 200713
  • Operating costs and profit analysis, 200713
• CHAPTER 7 KEY PRODUCTS AND COMPETITORS
  • Key findings
  • Overview
  • Oncology
  • Avastin
  • Rituxan
  • Herceptin
  • Tarceva
  • Immunology & inflammation
  • Ocrelizumab
  • Rituxan RA
  • Other
  • Lucentis
• CHAPTER 8 APPENDIX
  • R&D pipeline
  • References
  • Abbreviations
• TABLE OF TABLES
  • Table 1: Genentech PharmaVitae forecasts at a glance
  • Table 2: Genentech key product developments, 2008
  • Table 3: Genentech product deals and alliances, 2008
  • Table 4: Genentech technology deals and alliances, Q1 2008
  • Table 5: Genentech M&A activity, 2008
  • Table 6: Genentech company announcements, 2008
  • Table 7: Genentech future product milestones, 200810
  • Table 8: Genentech product portfolio overview ($m), 200107
  • Table 9: Genentech product portfolio overview ($m), 200713
  • Table 10: Genentech portfolio by therapy area ($m), 200107
  • Table 11: Genentech portfolio by therapy area ($m), 200713
  • Table 12: Genentech portfolio overview by geographic region ($m), 200107
  • Table 13: Genentech portfolio overview by geographic region ($m), 200713
  • Table 14: Genentech launch portfolio overview ($m), 200713
  • Table 15: Genentech core portfolio overview ($m), 200713
  • Table 16: Genentech expiry portfolio overview ($m), 200713
  • Table 17: Genentech portfolio overview by molecule type ($m), 200107
  • Table 18: Genentech product portfolio overview by molecule type ($m), 200713
  • Table 19: Genentech product portfolio overview by source ($m), 200107
  • Table 20: Genentech product portfolio overview by source ($m), 200713
  • Table 21: Total Genentech sales by business unit ($m), 200107
  • Table 22: Genentech profit and loss account ($m), 200107
  • Table 23: Genentech balance sheet ($m), 200107
  • Table 24: Genentech operating revenue/cost analysis ($m), 200107
  • Table 25: Genentech operating cost ratio analysis (% of total revenues), 200107
  • Table 26: Genentech operating cost ratio analysis (% of total revenues), 200713
  • Table 27: Genentech operating revenue/cost analysis ($m), 200713
  • Table 28: Key products overview
  • Table 29: Avastin: overview
  • Table 30: Avastin: sales forecast ($m), 200713
  • Table 31: Rituxan: overview
  • Table 32: Rituxan: sales forecast ($m), 200713
  • Table 33: Herceptin: overview
  • Table 34: Herceptin: sales forecast ($m), 200713
  • Table 35: Tarceva: overview
  • Table 36: Tarceva: sales forecast ($m), 200713
  • Table 37: ocrelizumab: overview
  • Table 38: ocrelizumab: sales forecast ($m), 200713
  • Table 39: Rituxan RA: overview
  • Table 40: Rituxan RA: sales forecast ($m), 200713
  • Table 41: Lucentis: overview
  • Table 42: Lucentis: sales forecast ($m), 200713
  • Table 43: Genentechs R&D pipeline (Phase Iregistration)
  • Table 44: Genentechs indication broadening pipeline (Phase Iregistration)
• TABLE OF FIGURES
  • Figure1: Genentech prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
  • Figure2: Genentechs financial performance ($m), 200113
  • Figure3: Genentech launch/core/expiry configuration ($m), 200713
  • Figure4: Avastins potential approvals within the forecast period
  • Figure5: Genentechs reliance on Avastin
  • Figure6: Genentech SWOT analysis
  • Figure7: Corporate structure
  • Figure8: Genentech prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
  • Figure9: Genentech key sales growth driver & resistors ($m), 200107
  • Figure10: Genentech key sales growth drivers & resistors ($m), 200713
  • Figure11: Genentech prescription pharmaceutical sales by therapy area ($m), 200113
  • Figure12: Genentech prescription pharma sales by therapy area (% of total), 200113
  • Figure13: Genentech prescription pharmaceutical sales by geographic region ($m), 200113
  • Figure14: Genentech growth drivers and resistors by geographic region ($m), 200107
  • Figure15: Genentech drivers and resistors by geographic region ($m), 200713
  • Figure16: Genentech prescription pharmaceutical sales by geographic region (% of total), 200113
  • Figure17: Genentech launch/core/expiry configuration ($m), 200713
  • Figure18: Genentech prescription pharmaceutical sales by molecule type ($m), 200113
  • Figure19: Genentech growth drivers and resistors by molecule type ($m), 200713
  • Figure20: Genentech prescription pharmaceutical sales by source ($m), 200113
  • Figure21: Genentech growth drivers and resistors by source ($m), 200107
  • Figure22: Genentech growth drivers and resistors by source ($m), 200713
  • Figure23: Genentech operating revenue/cost analysis ($m), 200113
  • Figure24: Genentech operating cost ratio analysis (% of total revenues), 200113